In this issue, Lee and colleagues1 present the results of the largest prospective clinical cohort study to date concerning 507 women with vulvar lichen sclerosus (VLS). The authors present evidence that poor compliance with topical corticosteroid (TCS) treatment predisposes patients to the development of vulvar cancer and scarring. They propose that initial treatment regimens should be selected using a variety of corticosteroid potencies based on the severity of signs at presentation. They also propose that maintenance treatment for VLS should be the norm, increasing or decreasing the potency of treatment as necessary. The authors recommend life-long specialist follow-up.
Cooper SM, Madnani N, Margesson L. Reduced Risk of Squamous Cell Carcinoma With Adequate Treatment of Vulvar Lichen Sclerosus. JAMA Dermatol. 2015;151(10):1059-1060. doi:10.1001/jamadermatol.2015.0644